[Efficacy of omalizumab in patients with severe asthma using the asthma health questionnaire and asthma control test].

BACKGROUND: The efficacy of anti-IgE antibody, omalizumab, was studied in patients with severe bronchial asthma. There have been reports stating that although omalizumab could not improve objective results, it has shown improvements in subjective symptoms of patients. The aim of this study is to evaluate the efficacy of omalizumab in severe bronchial asthma. METHODS: Thirteen patients were enrolled. Omalizumab was administered subcutaneously every 2 or 4 weeks based on serum IgE level and body weight of each patient. Pulmonary function tests, Asthma Control Test (ACT), Asthma Health Questionnaire-JAPAN (AHQ-JAPAN), number of emergency visits and dosage of methylprednisolone during a 16-week period were compared to the previous year. We examined the correlations between respiratory function, and ACT and AHQ-JAPAN. RESULTS: Treatment with omalizumab did not improve lung function. AHQ and ACT over the 16-week period significantly improved compared to baseline (p<0.01). The number of emergency visit and doses of methylprednisolone were significantly reduced compared to the previous year (p<0.01). CONCLUSION: Although treatment with omalizumab could not improve lung function, AHQ and ACT during the 16-week study period had significantly improved compared to baseline. Omalizumab significantly reduced the number of emergency visits and dosages of methylprednisolone.

Efficacy of long-term omalizumab therapy in patients with severe asthma.

BACKGROUND: The efficacy of omalizumab, an anti-immunoglobulin E (IgE) antibody, has been studied in patients with severe bronchial asthma. We conducted a study to evaluate, on the basis of both objective and subjective measures, the efficacy of omalizumab as a long-term therapy in patients with severe and persistent asthma. METHODS: Omalizumab was administered subcutaneously every two or four weeks. The results of pulmonary function tests, Asthma Control Test (ACT) and Asthma Health Questionnaire (AHQ)-33 scores, the dosage of methylprednisolone during the 12-month treatment period, and the number of emergency visits prior to the start of treatment with omalizumab were compared in patients pre- and post-treatment with omalizumab. RESULTS: Fourteen patients were enrolled in the study between June 2010 and February 2012. Ten patients completed the study. With omalizumab treatment, there was no improvement in lung function; however, the number of emergency visits (19.3 before treatment vs. 1.2 after treatment, p=0.020) and the dosage of methylprednisolone (871.5mg before treatment vs. 119.0mg after treatment, p=0.046) decreased significantly. ACT and AHQ-33 scores at 16 weeks after treatment were significantly better than baseline scores. Four patients continued treatment with omalizumab for four years, and a reduction in their corticosteroid usage was noted. CONCLUSIONS: Long-term omalizumab therapy in our patients was found to significantly reduce corticosteroid usage and the number of emergency visits. Long-term omalizumab therapy was effective and might have potential to reduce the frequency of asthma exacerbations. The trial has not been registered because it is not an intervention study.